aromasil has been researched along with Adverse Drug Event in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bilancia, D; Cairo, G; Cazzaniga, ME; Chiuri, VE; Ciccarese, M; Cusmai, A; De Matteis, E; Fabi, A; Febbraro, A; Forcignanò, R; Giampaglia, M; Giordano, G; Giotta, F; La Verde, N; Latorre, A; Lorusso, V; Lupo, LI; Maiello, E; Morritti, M; Moscetti, L; Palmiotti, G; Petrucelli, L; Romito, S; Scavelli, C; Surico, G | 1 |
| Ascione, G; Barone, CA; Bighin, C; Bordonaro, R; Cazzaniga, ME; Cognetti, F; Foglietta, J; Frassoldati, A; Generali, D; Goffredo, F; Ionta, MT; Latini, L; Mafodda, A; Mariani, G; Michelotti, A; Minisini, AM; Molino, A; Montemurro, F; Nolè, F; Nuzzo, F; Piacentini, F; Piovano, P; Portera, G; Riccardi, F; Roila, F; Romito, S; Sartori, D; Schirone, A; Simoncini, EL; Testore, F; Vici, P | 1 |
| Bachelot, T; Béal-Ardisson, D; Becuwe, C; Blot, E; Bürki, F; Cropet, C; Dauba, J; Diéras, V; Follana, P; Gouttebel, M; Guardiola, E; Jouannaud, C; Lavau-Denes, S; Moullet, I; Orfeuvre, H; Petit, T; Pujade-Lauraine, E; Stefani, L; Trager-Maury, S; Trédan, O | 1 |
| Bianchetti, S; Camozzi, M; Ciruelos, EM; Conte, P; Gavila, JG; Generali, D; Jerusalem, G; Lang, I; Lorizzo, K; Mardiak, J; Mariani, G; Martin, M; Michelotti, A; Montemurro, F; Naume, B; Neven, P; Simoncini, E; Tjan-Heijnen, VC | 1 |
| Cortesi, E; D'Onofrio, L; Fabbri, MA; Gamucci, T; Giuliani, R; Iezzi, L; Magri, V; Mancini, ML; Marchetti, P; Mauri, M; Mentuccia, L; Moscetti, L; Natoli, C; Pizzuti, L; Ramponi, S; Roma, CL; Ruggeri, EM; Santini, D; Sini, V; Sperduti, I; Vaccaro, A; Vici, P | 1 |
3 trial(s) available for aromasil and Adverse Drug Event
| Article | Year |
|---|---|
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Everolimus; Female; Humans; Italy; Middle Aged; Neoplasm Metastasis | 2017 |
A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Estrogen Receptor alpha; Female; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2 | 2016 |
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, e
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Everolimus; Female; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus | 2016 |
4 other study(ies) available for aromasil and Adverse Drug Event
| Article | Year |
|---|---|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Everolimus; Female; Humans; Italy; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Stomatitis | 2017 |
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Everolimus; Female; Humans; Italy; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Receptor, ErbB-2; Regression Analysis; Retrospective Studies; Treatment Outcome | 2016 |